ClinicalTrials.gg

Program

trifluridine tipiracil drug combination

Also written as “TAS-102”, “Trifluridine/Tipiracil” and “Trifluridine and Tipiracil Tablets”.

Its studies are mostly in Colorectal Neoplasms · Breast Neoplasms · Liver Neoplasms · Kidney Diseases · Small Cell Lung Carcinoma, led by 11 companies.

Furthest: phase 3, since May 24, 201225 company-led studies, 7 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka130 open or runningphase 3since May 24, 2012May 24, 2012none ahead
Sino Biopharmaceutical32 open or runningphase 3since Mar 6, 2026May 31, 2019Aug 2027phase 3 · NCT07483684
AbbVie11 open or runningphase 3since Apr 7, 2026Apr 7, 2026May 2029phase 3 · NCT07525206
Criterium11 open or runningphase 2since Apr 30, 2025Apr 30, 2025Dec 31, 2027phase 2 · NCT06992258
Elevar Therapeutics10 open or runningphase 1since Aug 26, 2019Aug 26, 2019none ahead
GamaMabs Pharma10 open or runningphase 2since Jan 8, 2019Jan 8, 2019none ahead
Gilead Sciences11 open or runningphase 2since Apr 7, 2026Apr 7, 2026Dec 2028phase 2 · NCT07527858
Jiangsu HengRui Medicine11 open or runningphase 3since Dec 26, 2023Dec 26, 2023none ahead
Lunan Pharmaceutical Group10 open or runningno phasesince Mar 19, 2026Mar 19, 2026none ahead
STCube11 open or runningphase 1since May 27, 2026May 27, 2026Jul 31, 2028phase 1 · NCT07656038
Takeda10 open or runningphase 2since Nov 20, 2015Nov 20, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since May 24, 2012.

  1. Jul 13, 2015Phase 3 study in Stomach NeoplasmsOtsuka · NCT02500043 · 507 enrolled · United States, Belarus, Belgium and more
  2. Nov 20, 2015Takeda’s first study: phase 2 study in Colorectal NeoplasmsNew to TakedaTakeda · NCT02613221 · 56 enrolled · Japan
  3. Jul 13, 2016Phase 2 study in Colorectal NeoplasmsOtsuka · NCT02860546 · 18 enrolled · United States
  4. Jan 8, 2019GamaMabs Pharma’s first study: phase 2 study in Colorectal NeoplasmsNew to GamaMabs PharmaGamaMabs Pharma · NCT03799731 · 65 enrolled · Belgium, Czechia
  5. May 31, 2019Sino Biopharmaceutical’s first study: phase 1 study in Colorectal NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03974594 · 64 enrolled · China
  6. Aug 26, 2019Elevar Therapeutics’ first study: phase 1 study in Colorectal NeoplasmsNew to Elevar TherapeuticsElevar Therapeutics · NCT04073615 · 29 enrolled · United States
  7. Dec 26, 2023Jiangsu HengRui Medicine’s first study: phase 3 study in Advanced Colorectal CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06199973 · 130 enrolled · China
  8. Apr 30, 2025Criterium’s first study: phase 2 study in Colorectal NeoplasmsNew to CriteriumCriterium · NCT06992258 · 120 planned · United States
  9. Jun 23, 2025Phase 2 study in RAS/BRAF Wild Type Colorectal CancerSino Biopharmaceutical · NCT07044908 · 72 planned · China
  10. Mar 6, 2026Phase 3 study in HER2 IHC3+ Advanced Colorectal CancerPhase 3 reachedSino Biopharmaceutical · NCT07483684 · 142 planned · China
  11. Mar 19, 2026Lunan Pharmaceutical Group’s first study: no phase study in Solid Tumor CancerNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT07492173 · 76 enrolled · China
  12. Apr 7, 2026Gilead Sciences’ first study: phase 2 study in Advanced Microsatellite Stable Colorectal CancerNew to Gilead SciencesGilead Sciences · NCT07527858 · 170 planned · United States, Australia, South Korea and more
  13. Apr 7, 2026AbbVie’s first study: phase 3 study in Colorectal NeoplasmsNew to AbbVieAbbVie · NCT07525206 · 990 planned · United States, Belgium, China and more
  14. May 27, 2026STCube’s first study: phase 1 study in Colonrectal Cancer (CRC)New to STCubeSTCube · NCT07656038 · 45 planned

Ahead

  1. Aug 2027Primary completion: phase 3 study in HER2 IHC3+ Advanced Colorectal CancerSino Biopharmaceutical · NCT07483684
  2. Dec 31, 2027Primary completion: phase 2 study in Colorectal NeoplasmsCriterium · NCT06992258
  3. Jul 31, 2028Primary completion: phase 1 study in Colonrectal Cancer (CRC)STCube · NCT07656038
  4. Dec 2028Primary completion: phase 2 study in Advanced Microsatellite Stable Colorectal CancerGilead Sciences · NCT07527858

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07656038Colonrectal Cancer (CRC)1Not yet recruitingSTCubeJul 31, 202845
NCT07527858Advanced Microsatellite Stable Colorectal Cancer · United States, Australia, South Korea and more2RecruitingGilead SciencesDec 2028170
NCT07525206Colorectal Neoplasms · United States, Belgium, China and more3RecruitingAbbVieMay 2029990
NCT07492173Solid Tumor Cancer · China–CompletedLunan Pharmaceutical GroupJun 25, 202376
NCT07483684HER2 IHC3+ Advanced Colorectal Cancer · China3Not yet recruitingSino BiopharmaceuticalAug 2027142
NCT07044908RAS/BRAF Wild Type Colorectal Cancer · China2RecruitingSino BiopharmaceuticalJul 202672
NCT06992258Colorectal Neoplasms · United States2RecruitingCriteriumDec 31, 2027120
NCT06199973Advanced Colorectal Cancer · China3Active, not recruitingJiangsu HengRui MedicineApr 2026130
NCT04073615Colorectal Neoplasms · United States1TerminatedElevar TherapeuticsMay 31, 202329
NCT03974594Colorectal Neoplasms · China1CompletedSino BiopharmaceuticalJul 16, 201964
NCT03799731Colorectal Neoplasms · Belgium, Czechia2CompletedGamaMabs PharmaJan 19, 202165
NCT02860546Colorectal Neoplasms · United States2CompletedOtsukaAug 201718
NCT02613221Colorectal Neoplasms · Japan2CompletedTakedaOct 6, 201756
NCT02500043Stomach Neoplasms · United States, Belarus, Belgium and more3CompletedOtsukaApr 30, 2018507
NCT02301117Kidney Diseases · United States, Czechia, Serbia1CompletedOtsukaJun 19, 201943
NCT02301104Liver Neoplasms · United States1CompletedOtsukaJun 201624
NCT02261532Advanced or Metastatic Solid Tumors · China1CompletedOtsukaOct 201515
NCT02031055Advanced Solid Tumors · United States1CompletedOtsukaNov 20148
NCT01955837Colorectal Neoplasms · China, Korea, Republic of, Thailand3CompletedOtsukaFeb 16, 2016406
NCT01916447Advanced Gastrointestinal Tumors · United States1CompletedOtsukaSep 201765
NCT01904253Small Cell Lung Carcinoma · Germany, Italy, Japan2TerminatedOtsukaJun 201418
NCT01874522Advanced Solid Tumors (Excluding Breast Cancer) · United States1CompletedOtsukaAug 201546
NCT01867879Advanced Solid Tumors (Excluding Breast Cancer) · United States1CompletedOtsukaAug 201444
NCT01867866Advanced Solid Tumors · United States1CompletedOtsukaOct 201344
NCT01607957Colorectal Neoplasms · United States, Australia, Austria and more3CompletedOtsukaJan 31, 2014800

How it is read

Names in the registry

  • “TAS-102”, 11 entries
  • “Trifluridine/Tipiracil”, 3 entries
  • “Trifluridine and Tipiracil Tablets”, 2 entries
  • “Trifluridine-Tipiracil”, 1 entry
  • “Fruquintinib+ Lonsurf (trifluridine and tipiracil)”, 1 entry

Codes read as this program: TAS102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.